Videos

Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).

Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.

Adding immunotherapy to chemotherapy is the new standard-of-care treatment for advanced or recurrent endometrial cancer, according to Eirwen Miller, MD.

Skye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.

Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.

Hatem Soliman, MD, discusses second- and third-line strategies being used for the treatment of patients with HER2-positive metastatic breast cancer.

Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.

Aaron T. Gerds, MD, MS, explains the current remaining unmet needs in the treatment of patients with myelofibrosis.

Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.

The push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.

Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.

Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.

Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.

Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.

Nathan Bahary, MD, PhD, discusses how Allegheny Health Network has been able to combat the recent chemotherapy drug shortages seen nationwide.

Joshua K. Sabari, MD, discusses the importance of targeting the KRAS biomarker and what inhibitors currently exist for patients with KRAS G12C-mutant advanced solid tumors.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Michael Wang, MD, discusses where unmet needs still exist for patients with relapsed/refractory mantle cell lymphoma.

Petros Grivas, MD, PhD, discusses the design and end points of the phase 2 KEYNOTE-057 trial.

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.

Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.

Manmeet Ahluwalia, MD, discusses brain metastases in patient with biomarker-driven lung cancer and outcomes of these patients.

A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.

A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.

A phase 3 study of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma is discussed by Binod Dhakal, MD, MS.

Jonathan C. Trent, MD, PhD, discusses the methods, design, and results from the INTRIGUE study in advanced gastrointestinal stromal tumor.

Prerna Mewawalla, MD, discusses how she approaches the choice of therapy for relapsed/refractory multiple myeloma now that many different options are available for patients.